催眠药
医学
白细胞减少症
中性粒细胞减少症
内科学
中止
不利影响
紫杉醇
胃肠病学
癌症
肿瘤科
联合疗法
化疗
作者
Kohei Murakami,Atsushi Takeno,Toru Masuzawa,Ayako Imada,Koki Takase,Keisuke Toya,Yoshiro Yukawa,Kenji Kawai,Takuya Sakamoto,Yoshiteru Katsura,Yoshiaki Ohmura,Yoshinori Kagawa,Taishi Hata,Yutaka Takeda,Kohei Murata
摘要
We retrospectively evaluated the efficacy and feasibility of the combination of nab-paclitaxel plus ramucirumab(nab-PTX plus RAM)for the treatment of unresectable or recurrent gastric cancer. Sixteen patients received nab-PTX plus RAM. The overall response rate was 37.5%, and disease control rate was 87.5%. The median progression-free survival was 5.0 months. Grade 3 or higher adverse events(neutropenia: 62.5%, leukopenia: 18.8%, decrease appetite: 6.3%, hypertension: 6.3%, and proteinuria: 12.5%)were observed. Although dose reduction of nab-PTX was required in 93.8% of the patients, no adverse event that led to the discontinuation of treatment. Nab-PTX plus RAM combination therapy showed promising efficacy and manageable toxicities and could be a viable treatment option for patients with advanced gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI